We are live on ! Find out more
FBT icon

First Trust NYSE Arca Biotechnology Index Fund

154 hedge funds and large institutions have $622M invested in First Trust NYSE Arca Biotechnology Index Fund in 2018 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 51 increasing their positions, 37 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

260% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 10

150% more funds holding in top 10

Funds holding in top 10: 25 (+3)

133% more call options, than puts

Call options by funds: $4.67M | Put options by funds: $2.01M

38% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 37

25% more capital invested

Capital invested by funds: $497M → $622M (+$126M)

18% more funds holding

Funds holding: 130154 (+24)

3.28% more ownership

Funds ownership: 40.9%44.18% (+3.3%)

Holders
154
Holders Change
+24
Holders Change %
+18.46%
% of All Funds
3.53%
Holding in Top 10
5
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+150%
% of All Funds
0.11%
New
36
Increased
51
Reduced
37
Closed
10
Calls
$4.67M
Puts
$2.01M
Net Calls
+$2.66M
Net Calls Change
+$105K

FBT Hedge Fund Activity: Q1 2018 in Review

154 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in First Trust NYSE Arca Biotechnology Index Fund (FBT) for Q1 2018, worth a combined $622M — up 25% from $497M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new FBT positions and 10 closed out — a net gain of 26 holders — while 51 added to existing stakes and 37 trimmed.

The largest buyer was Navellier & Associates, opening a new position worth an estimated $23.3M. The largest seller was Goldman Sachs, cutting an estimated $3.34M.

  • 154 institutional investors held First Trust NYSE Arca Biotechnology Index Fund (FBT) as of Q1 2018, up from 130 in Q4 2017.
  • Funds reported $622M of First Trust NYSE Arca Biotechnology Index Fund stock for Q1 2018, up 25% quarter-over-quarter.
  • 36 funds opened new First Trust NYSE Arca Biotechnology Index Fund positions in Q1 2018 and 10 closed out, a net change of +26 holders.
  • The largest First Trust NYSE Arca Biotechnology Index Fund buyer in Q1 2018 was Navellier & Associates, an estimated $23.3M added.
  • The largest First Trust NYSE Arca Biotechnology Index Fund seller in Q1 2018 was Goldman Sachs, an estimated $3.34M sold.

Based on aggregated 13F filings for Q1 2018.